Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.64 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | LDHA | P00338 | 2/20 | 0.48 |
| ▸ | LDHB | P07195 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.48 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL436599 | 0.85 | MEN1 (0.51) | PDPK1ALDH1A1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL435642 | 0.85 | L3MBTL1 (0.63) | ALDH1A1SMN1; SMN2MAPTKDM4ELMNA | |
| SCHEMBL29110241 | 0.81 | PDPK1 (0.58) | PDPK1HSD11B1LDHALDHBALDH1A1 | |
| SCHEMBL8532315 | 0.79 | PDPK1 (0.55) | PDPK1HSD11B1LDHALDHBALDH1A1 | |
| SCHEMBL658661 | 0.78 | PDPK1 (1.00) | PDPK1HSD11B1LDHALDHBPTPN1 | |
| SCHEMBL658415 | 0.78 | PDPK1 (0.66) | PDPK1HSD11B1LDHALDHBMAPT | |
| SCHEMBL2304585 | 0.77 | ACP3 (0.56) | PDPK1HSD11B1ALDH1A1PTPN1NR4A1 | |
| SCHEMBL13385708 | 0.76 | PDPK1 (0.59) | PDPK1HSD11B1LDHALDHBSMN1; SMN2 | |
| SCHEMBL18860300 | 0.75 | PTPN1 (0.59) | PDPK1HSD11B1ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL19642328 | 0.75 | PDPK1 (0.65) | PDPK1HSD11B1ALDH1A1MAPTPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217073-B2 | Pyrrole derivatives as therapeutic compounds | MYREXIS, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-8217073-B2 | Pyrrole derivatives as therapeutic compounds | MYREXIS, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-20120065241-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYREXIS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065241-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYREXIS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20100216862-A1 | Pyrrole Derivatives As Therapeutic Compounds | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216862-A1 | Pyrrole Derivatives As Therapeutic Compounds | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-7714022-B2 | Pyrrole derivatives as therapeutic compounds | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7714022-B2 | Pyrrole derivatives as therapeutic compounds | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090253768-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090253768-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2009-10-08 | — | — | US | disclosed |
| US-20080249158-A1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249158-A1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065241-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | NLN, SLC18A2, GOLT1B | PDPK1 549/4885HSD11B1 4509/4885LDHA 3222/4885 |
| US-20100216862-A1 | Pyrrole Derivatives As Therapeutic Compounds | APP, PSEN2, PSEN1 | PDPK1 131/4885HSD11B1 3697/4885LDHA 3212/4885 |
| US-20080249158-A1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | APP, PSEN2, PSEN1 | PDPK1 131/4885HSD11B1 3697/4885LDHA 3212/4885 |
| US-20090253768-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | NLN, SLC18A2, GOLT1B | PDPK1 549/4885HSD11B1 4509/4885LDHA 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.